Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 14

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 14
---
ens Incorporation Limited, a wholly-owned subsidiary of Aptorum Group. |
| ● | “VIE” refers to a variable interest entity.                                                  |

<div align='center'>INDUSTRY AND MARKET DATA</div>

This prospectus includes information
with respect to market and industry conditions and market share from third-party sources or based upon estimates using such sources when
available. We have not, directly or indirectly, sponsored or participated in the publication of any of such materials. We believe that
such information and estimates are reasonable and reliable. We also assume the information extracted from publications of third-party
sources has been accurately reproduced. We understand that the Company would be liable for the information included in this prospectus
if any part of the information was incorrect, misleading or imprecise to a material extent.

<div align='center'>vii</div>

PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully read the entire prospectus, including our financial statements and the related notes and management’s discussion and analysis incorporated herein by reference. You should also consider, among other things, the matters described under “Risk Factors” in each case appearing elsewhere in this prospectus. Unless otherwise stated, all references to “us,” “our,” “Aptorum,” “we,” the “Company,” the “group” and similar designations refer to Aptorum Group Limited, a Cayman Islands exempted company with limited liability and all references to “DiamiR” refer to DiamiR Biosciences Corp., a Delaware corporation. Business Overview of Aptorum The Company is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company now focuses all of its efforts on R&D. In the past, the Company had provided clinic services. While the Company may re-commence clinic services in the future, as of December 31, 2024 and the date hereof, it only operates in one segment. Our goal is to develop a broad range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components of our strategy for achieving this goal include: (for details of our strategy, See “Business Overview – Company’s Strategy”)

| ●